A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
- Conditions
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 294
- Registration Number
- NCT06586294
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hanzhou, Zhejiang, China
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 172
- Registration Number
- NCT06560112
A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Akeso
- Target Recruit Count
- 280
- Registration Number
- NCT06530251
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan, Shandong, China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Akeso
- Target Recruit Count
- 180
- Registration Number
- NCT06387420
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 420
- Registration Number
- NCT06383468
- Locations
- 🇨🇳
Beijing Friendship Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Akeso
- Target Recruit Count
- 510
- Registration Number
- NCT06378697
- Locations
- 🇨🇳
1027-Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳1005-Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳1030-Jieyang People's Hospital, Jieyang, Guangdong, China
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 469
- Registration Number
- NCT06371157
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanxi Cancer Hospital, Taiyuan, Shanxi, China
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 506
- Registration Number
- NCT06341335
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 34
- Registration Number
- NCT06281704
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT06196203
- Locations
- 🇺🇸
Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States